Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) Equity Average: 2020-2025

Historic Equity Average for Harmony Biosciences Holdings (HRMY) over the last 5 years, with Sep 2025 value amounting to $804.1 million.

  • Harmony Biosciences Holdings' Equity Average rose 41.64% to $804.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $804.1 million, marking a year-over-year increase of 41.64%. This contributed to the annual value of $563.1 million for FY2024, which is 29.47% up from last year.
  • As of Q3 2025, Harmony Biosciences Holdings' Equity Average stood at $804.1 million, which was up 7.67% from $746.8 million recorded in Q2 2025.
  • Over the past 5 years, Harmony Biosciences Holdings' Equity Average peaked at $804.1 million during Q3 2025, and registered a low of $102.5 million during Q1 2021.
  • Moreover, its 3-year median value for Equity Average was $527.0 million (2024), whereas its average is $572.6 million.
  • Data for Harmony Biosciences Holdings' Equity Average shows a peak YoY surged of 120.58% (in 2022) over the last 5 years.
  • Over the past 5 years, Harmony Biosciences Holdings' Equity Average (Quarterly) stood at $169.3 million in 2021, then soared by 120.58% to $373.4 million in 2022, then rose by 27.00% to $474.2 million in 2023, then skyrocketed by 32.44% to $628.0 million in 2024, then spiked by 41.64% to $804.1 million in 2025.
  • Its last three reported values are $804.1 million in Q3 2025, $746.8 million for Q2 2025, and $689.8 million during Q1 2025.